Clinical Trials Logo

Clinical Trial Summary

To evaluate the safety, immune-response and efficacy of GSK Biologicals’ EBV vaccine in a population at risk of developing infectious mononucleosis. Each subject will receive three doses of vaccine or placebo during the study period.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention


Related Conditions & MeSH terms

  • Epstein Barr Virus (EBV) Infection

NCT number NCT00430534
Study type Interventional
Source Henogen
Contact
Status Completed
Phase Phase 2